why choose us

First received: October 19, 2022

Clinical Trial: Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Non Hodgkin's Lymphoma Refractory/Relapsed

Study Type: INTERVENTIONAL


Official Title: Open-label, Phase 1 Study of CD19 t-haNK as a Single Agent and in Combination With an IL-15 Superagonist (N-803) and Rituximab in Subjects With Selected CD19+ and CD20+ Relapsed/Refractory B-Cell

Brief Summary: Open-label, Phase 1 Study of CD19 t-haNK as a Single Agent and in Combination With an IL-15 Superagonist (N-803) and Rituximab in Subjects With Selected CD19+ and CD20+ Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.Up to 20 subjects will be enrolled and randomized 1:1 to 1 of 2 cohorts, as outlined below.The initial 3 subjects will be sequentially enrolled in a staggered fashion, with a 7 day interval between each subject to enable the capture and monitoring of any acute and subacute toxicities.

Read more